EV POPULATION of eligible Brivanib alaninate BMS-582664 patients, median TTP. Months and the median overall survival. Months. Before the clinical efficacy and we made an unplanned pregnancy, the post-hoc analysis for the RBC tipifarnib combined with AND fulvestrant earlier. Of the nine patients who were either HE na F ETsensitive or illness had were five PR and SD had it, what’s a CBR Among patients with disease were resistant and six had PR and four had SD for at least a few weeks, is that a CBR Among patients with AI disease-resistant patients a clinical benefit. Treatment administered to all patients, and side effects that u at least one dose of tipifarnib again in the analysis of s Purity included. A total treatment cycles were administered. In M Rz two patients were still in treatment after cycles.
Adverse events are summarized in the table. Shades bcl-2 the h Most common adverse events that were at least patients nausea, diarrhea, vomiting, neutropenia, to chemistry, Increased neuropathy, rash, fatigue, shortness of breath, Hte serum creatinine, thrombosis, anxiety, hyperglycemia Mie, Hypokalz mie and anorexia. The majority of the patients discontinued treatment for progressive disease. Other reasons for discontinuation included toxicity t in three patients, and withdrawal of consent in two patients. Eight patients ben Saturated dose reduction of tipifarnib achieve six clinical benefit. Reasons for the reduction of the dose or tipifarnib nausea degree h from, Diarrhea, trembling, neutropenia, increased Hte creatinine, fatigue and confusion.
Discussion We have a phase II trial of the FTI tipifarnib in combination with fulvestrant selective ER down regulator f Rderf HIGEN postmenopausal women with HR positive MBC. Eligible patients had not again U prior chemotherapy for MBC, with about two-thirds had disease that was resistant to AI therapy, and a third of them, again Any u ET for metastatic disease. The prime Endpoint was re CBR took an endpoint, the h Frequently in studies that use the ET for MBC. We decided to carry us to the analysis of futility before the end of our study, since the results of a randomized phase II study showed no benefit for tipifarnib, when added to the AI letrozole in tamoxifen-resistant disease. The study included patients who were randomized to: fashion, received letrozole in combination with either placebo or tipifarnib. The dosage and tipifarnib mg bid was days, as in our study.
The CBR is in the letrozole tipifarnib arm and letrozole in the placebo group. There was no significant difference in the duration of response, survival time of disease progression or. Based on the results of this study and the fact that the analysis of our study futility decided that we could not get a given CBR, we decided not to be collected again. Although our study does not fulfill its prime Ren endpoint, and tipifarnib not seem hen the effectiveness of letrozole to increased, Evaluating the combination of tipifarnib fulvestrant in AI-resistant disease set can be justified for several reasons. First, is a more effective inhibitor fulvestrant warning device AI not stero Ans as letrozole for the first ligand-receptor interaction Bl cke Deteriorated and emergency, w While the latter only reduces